Many treatment guidelines for psoriasis rely heavily on body surface area (BSA) involvement to determine disease severity and eligibility for systemic therapies like biologics. Traditionally, patients with less than 10% BSA involvementespecially Psoriasis harbors multiple pathogenic type 17 T cell subsets: Selective modulation by risankizumab Journal of Allergy and Clinical Immunology Frontiers Gut microbiota and psoriasis: pathogenesis, targeted therapy, and future directions Pustular Psoriasis and Acute Generalized Exanthematous Pustulosis